Moderna, Inc.

MRNA

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US5,800 employeesmodernatx.com

$49.11

-0.92(-1.84%)

Mkt Cap $19.4B

$22.36

$57.80

52-Week Range

At a Glance

AI-generated

Moderna, Inc.

Revenue breakdown: Product Sales (64.5%), COVID19 (32.1%), Product And Service Other (1.3%).

8-K

Moderna, Inc. reported Q4 2025 revenue of $678 million and a GAAP net loss of $(826) million, or $(2.11) per share. The Company reiterated its 2026 financial framework targeting up to 10% revenue growth and provided updates on regulatory submissions and clinical pipeline milestones.

$19.4B

Market Cap

$2.0B

Revenue

-$2.8B

Net Income

Employees5,800

Fundamentals

How The Business Makes Money

Revenue by Segment

Product Sales64.5%($23.2B)

COVID1932.1%($11.6B)

Product And Service Other1.3%($460M)

Grant0.9%($306M)

Collaboration Arrangement Including Arrangements With Affiliate0.8%($288M)

Stand Ready Manufacturing Revenue0.2%($80M)

License And Royalty0.1%($53M)

RSV0.1%($33M)

Revenue by Geography

US40.2%($9.5B)

Rest Of World21.8%($5.1B)

Rest Of The World21.2%($5.0B)

Europe16.9%($4.0B)

Activity

What Changed Recently

Material Agreement

Mar 4, 2026

. Entry into a Material Definitive Agreement. On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Comp

Financial Results

Feb 12, 2026

Results of Operations and Financial Condition. On February 13, 2026, Moderna, Inc. issued a press release announcing its financial results for the fourth quarte

Financial Results

Jan 11, 2026

. Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01. The information contained in It

Regulation FD

Feb 10, 2026

, as well as Exhibit 99.1, to this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Secu

Regulation FD

Jan 4, 2026

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

Peer Companies

Company	Price	Change	Market Cap	P/E
RVMDRevolution Medicines, Inc...	$99.12	+0.49%	$19.6B	-16.2
BBIOBridgeBio Pharma, Inc.	$73.22	-1.65%	$14.2B	-18.8
MDGLMadrigal Pharmaceuticals,...	$544.43	+2.75%	$12.5B	-34.8
EXELExelixis, Inc.	$43.87	-0.39%	$11.8B	14.4
JAZZJazz Pharmaceuticals plc	$186.84	-0.76%	$11.5B	-31.2
BMRNBioMarin Pharmaceutical I...	$55.51	-3.03%	$10.7B	30.1
TECHBio-Techne Corporation	$53.13	-0.66%	$8.3B	99.9
HALOHalozyme Therapeutics, In...	$64.47	-1.42%	$7.6B	23.3

Analyst View

Company Profile

CIK0001682852

ISINUS60770K1079

CUSIP60770K107

Phone617 714 6500

Address200 Technology Square, Cambridge, MA, 02139, US

SEC EDGAR